Bulk Email Application

Biologics License Application for Subcutaneous Formulation of "LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority R…

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, 'Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...

Some results have been hidden because they may be inaccessible to you